ADA Scientific Sessions 2025 Abstract

Leveraging Real-World Evidence to Analyze Changes in Prescribing of GLP-1 Receptor Agonists in the United States

By Polina Kukhareva, Kensaku Kawamoto

Study in peoplePopulations

The paper

Polina Kukhareva, Kensaku Kawamoto

Salt Lake City

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, oral 304-OR

doi.org/10.2337/db25-304-or

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression